Novartis: good results for Sjögren’s syndrome remedy
Keystone-SDA
Good news in research for Novartis. The pharmaceutical giant has achieved the hoped-for results for Ianalumab, a candidate for the treatment of Sjögren’s Syndrome, a serious autoimmune disease.
+Get the most important news from Switzerland in your inbox
In the phase III trials Neptunus-1 and Neptunus-2, the therapy reduced disease activity in patients, a statement said today. The data will now be presented at a medical congress and forwarded to health authorities worldwide.
Ianalumab has the potential to become the only targeted treatment for patients with Sjögren’s Syndrome, according to Novartis. According to experts, the product could bring the group more than CHF1 billion ($1.24 billion) per year in the future.
Ianalumab (VAY736) is a next-generation human antibody that could treat several B-cell-related diseases, including the aforementioned Sjögren’s Syndrome, but also immune thrombocytopenia (PTI) and systemic lupus erythematosus (SLE). The therapy is the result of a collaboration with Morphosys, a company acquired by Novartis in 2024.
Translated from Italian by DeepL/jdp
We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.
Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
If you have any questions about how we work, write to us at english@swissinfo.ch.
